Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69–v82. https://doi.org/10.1093/annonc/mdw025.

Article  CAS  PubMed  Google Scholar 

Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2019;54:798–809. https://doi.org/10.1038/s41409-018-0373-4.

Article  Google Scholar 

Giebel S, Labopin M, Socié G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139–49. https://doi.org/10.3324/haematol.2016.145631.

Article  PubMed  PubMed Central  Google Scholar 

Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transpl. 2006;12:438–53. https://doi.org/10.1016/j.bbmt.2005.12.029.

Article  CAS  Google Scholar 

Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transpl. 2016;51:351–7. https://doi.org/10.1038/bmt.2015.278.

Article  CAS  Google Scholar 

Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, et al. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:778–85. https://doi.org/10.1002/ajh.25091.

Article  CAS  PubMed  Google Scholar 

Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, et al. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019;106:212–9. https://doi.org/10.1016/j.ejca.2018.11.003.

Article  CAS  PubMed  Google Scholar 

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3:670–80. https://doi.org/10.1182/bloodadvances.2018027003.

Article  PubMed  PubMed Central  Google Scholar 

Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transpl. 2020;55:126–36. https://doi.org/10.1038/s41409-019-0624-z.

Article  Google Scholar 

Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64. https://doi.org/10.1016/s1470-2045(09)70225-6.

Article  CAS  PubMed  Google Scholar 

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53. https://doi.org/10.1056/NEJMoa1506002.

Article  CAS  PubMed  Google Scholar 

Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.

Article  CAS  Google Scholar 

Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transpl. 2019;54:432–41. https://doi.org/10.1038/s41409-018-0279-1.

Article  CAS  Google Scholar 

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024–31. https://doi.org/10.1182/blood-2015-01-623991.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82. https://doi.org/10.1182/blood.2021011281.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46 https://doi.org/10.1186/s13045-020-00882-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Malki MM, Tsai NC, Palmer J, Mokhtari S, Tsai W, Cao T, et al. Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Adv. 2021;5:2650–9. https://doi.org/10.1182/bloodadvances.2021004192.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2021;39:1971–82. https://doi.org/10.1200/jco.20.03502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224–30. https://doi.org/10.1182/blood-2009-11-251595.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817–27. https://doi.org/10.1182/blood-2014-07-587477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanakry CG, O’Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32:3497–505. https://doi.org/10.1200/jco.2013.54.0625.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, et al. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017;129:1389–93. https://doi.org/10.1182/blood-2016-09-737825.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87 https://doi.org/10.1186/s13045-020-00923-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MW, van Roessel C, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023. https://doi.org/10.1111/bjh.19031.

Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2023. https://doi.org/10.1002/cncr.35004.

Nagler A, Kanate AS, Labopin M, Ciceri F, Angelucci E, Koc Y, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica. 2021;106:1591–8. https://doi.org/10.3324/haematol.2020.247296.

Article  CAS  PubMed